An accompany commentary notes that a clear strength of the study, apart from the important and innovative primary endpoint, is the application of both drugs in a weekly regimen and at a dose that does not result in a change in intensity, thus enabling accurate comparison of the treatment schedules. A possible drawback of the study, however, is the fairly high proportion of patients who underwent either interval debulking surgery or no surgery at all, which raises the question whether the results can be translated to routine practice. Furthermore, as there was no difference for progression-free survival (PFS) in this superiority trial, a possible inferior PFS of the weekly regimen cannot be ruled out, and both regimens should not be judged equally effective. Nevertheless, these findings add important new aspects to the best treatment of patients undergoing first-line chemotherapy for advanced ovarian cancer, and inform the design of future trials.